MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MNKD Stock surged +2.04% Today — RQD Quant Desk Flash
$3.50 +2.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.51
MannKind Corporation (MNKD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $1.13B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.51 (+0.18%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY MNKD SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (21% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 55.6 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$3.29-7.6% Next Q
55
Q2 (-2Q)Grade C$3.04+4.9% Next Q
58
Q3 (-1Q)Grade C$3.19+9.7% Next Q
60
CurrentGrade C$3.50+0.9% Hist 90D α
63
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail
Even with a 63/100 (C) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 89.8% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.58) or 200D SMA ($3.73) invalidates the momentum regime and cuts Target Base ($3.58) toward Bear Floor ($2.79).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MNKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MNKD Stock surged +2.04% Today — RQD Quant Desk Flash
MannKind Corporation (MNKD) surged +2.04% to $3.50, trading at 30% of its 52-week range ($2.23 – $6.51). Solid 92% profit margin (55% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 30% of its 52-week range ($2.23 – $6.51) with RSI-14 at 55.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.1% around $3.50 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 92.3% gross margin and $13.7M annual free cash flow.
Live MNKD Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (MNKD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.67%▼ DESCENDING CHANNEL
2026-10-30O $3.50H $3.57L $3.45C $3.50VOL 2.01M
RES: $4.21SUP: $2.73SMA50: $3.58SMA200: $3.73
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.7%/yr Implied 5Y Growth
vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)
Health Care Rank #158 of 1016
⚔️ HROW vs MNKD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MNKD vs. HROW, SPTX, CTY, AVLN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #158 by composite RQD confidence (63/100, grade C) and #348 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, MNKD leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with MNKD at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MNKD
ACTIVE
MannKind Corporation | C | 63/100 | — | 92.3% | 54.5% | +2.04% | $1.13B | Benchmark Subject |
| HROW Harrow Inc. | B- | 71/100 | — | 75.1% | 42.9% | +2.04% | $1.12B | /hrow-vs-mnkd → |
| SPTX Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | /sptx-vs-mnkd → |
| CTY City Therapeutics Inc. | C- | 61/100 | — | — | — | +2.26% | $1.11B | /cty-vs-mnkd → |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-mnkd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $349.0M | $5.9M | $18.3M | $13.7M | $792.2M | — |
| FY2024 (FY) | 2024-12-31 | $285.5M | $27.6M | $42.5M | $32.8M | $393.8M | — |
| FY2023 (FY) | 2023-12-31 | $199.0M | -$11.9M | $34.1M | $34.1M | — | — |
3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, MannKind Corporation (NASDAQ: MNKD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $3.50 (+2.04% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #158 in composite RQD confidence.
How does MNKD compare to HROW and SPTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, HROW (Harrow Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B) and SPTX (Seaport Therapeutics Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, MNKD leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MNKD?
Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?
MNKD last traded at $3.50 (+2.04% on volume of 2,276,272 shares), positioning the stock -2.23% below its 50-day simple moving average ($3.58) and -6.17% below its 200-day simple moving average ($3.73). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 29.7% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.1% ($3.11 to $3.89).
MNKD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MNKD stock moving today?
Why MNKD Stock surged +2.04% Today — RQD Quant Desk Flash. Solid 92% profit margin (55% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.